Viscosupp Injection for Orth/Musculoskeletal: 93.9% of denials overturned
In 824 California IMR decisions from 2018 to 2025, reviewers overturned 774 (93.9%). In the last five years: 97.9% of 520. 801 were medical-necessity disputes, 23 experimental/investigational.
By year (last five)
| Year | Decisions | Overturned |
|---|---|---|
| 2021 | 136 | 99.3% |
| 2022 | 110 | 99.1% |
| 2023 | 89 | 94.4% |
| 2024 | 97 | 96.9% |
| 2025 | 88 | 98.9% |
What the findings mention
| What the findings mention | Decisions | Overturned | All decisions here |
|---|---|---|---|
| Published evidence citedThe findings refer to peer-reviewed or published evidence. | 544 | 94.7% | 93.9% |
| Prior therapies failedThe findings mention treatments that were tried without adequate response. | 366 | 97.3% | 93.9% |
| Guidelines or criteria citedThe findings cite guidelines, criteria or a standard of care. | 70 | 82.9% | 93.9% |
| Alternatives contraindicatedThe findings mention a contraindication to the plan's preferred option. | 11 | 100.0% | 93.9% |
| Records did not supportThe findings say the documentation did not show what was needed (usually an upheld denial). | 10 | 30.0% | 93.9% |
Keyword matches on the reviewer’s findings, not causes. A tag that appears mostly in overturned decisions is worth documenting in an appeal; it is not a guarantee.
From recent overturned decisions
“The physician reviewer found that a patient has requested authorization and coverage for Euflexxa series injections to the right knee. Per the medical literature, although viscosupplementation may relieve knee pain in some individuals with osteoarthritis, it is not known as to which individuals will benefit. The current evidence is limited, and guidelines from organizations such as the American Academy of …”
“The physician reviewer found that a patient has requested reimbursement and prospective authorization and coverage for a series of Orthovisc injections to the left knee and/or a series of Orthovisc injections to the right knee. According to the medical literature, viscosupplementation is only recommended for patients with osteoarthritis of the knees with a history of lasting benefit from prior injections, …”
“The physician reviewer found that Nature of Statutory Criteria/Case Summary: A patient has requested authorization and coverage for an Euflexxa injection series administered to the right knee. In this case, the patient has documented osteoarthritis of the right knee. The record reveals that conservative measures have been attempted, including physical therapy and home exercises. The patient is unable to take …”
And one the reviewer upheld
“The physician reviewer found that Nature of Statutory Criteria/Case Summary: A patient has requested authorization and coverage for right knee hyaluronan or derivative; Durolane for intra-articular injection. According to a review and meta-analysis, viscosupplementation is associated with an increased risk of serious adverse events, including pseudoseptic reactions and septic arthritis. The findings in this study do not support the broad …”
- California only: these are decisions by independent reviewers under California's IMR program (plans regulated by the Department of Managed Health Care). Other states and self-funded employer plans use different reviewers and rules.
- Selection: only denials that a member took all the way to IMR appear. Most denials are never appealed, and the ones that reach an external reviewer are not a random sample.
- Overturned means the reviewer disagreed with the plan; it does not mean the treatment worked or that a similar request will be approved.
- Argument tags are keyword matches on the reviewer's findings. They describe what the findings mention, not why the case was decided.
- Categories are DMHC's own labels (treatment sub-category and diagnosis category); 'Other' is a catch-all and is excluded from rankings.
Source: California Department of Managed Health Care, Independent Medical Review (IMR) Determinations, Trend (CHHS Open Data). Public California government data; Apellica's aggregates and tags are CC BY 4.0.
Questions
How often were Viscosupp Injection denials for Orth/Musculoskeletal overturned?
In 824 California IMR decisions from 2018 to 2025, reviewers overturned 774 (93.9%). In the last five years: 97.9% of 520. 801 were medical-necessity disputes, 23 experimental/investigational.
What should an appeal document, based on these findings?
Whatever the plan's criteria ask for, shown in the record: the treatments already tried and their results, contraindications to the plan's preferred option, the guideline or evidence that supports the request, and the treating clinician's reasoning written to the criteria. The tag table shows which of these the reviewers mentioned most in overturned cases.
Does a California IMR result apply to my plan?
Only California plans regulated by the Department of Managed Health Care go to IMR. Other states and self-funded employer plans use different reviewers, but they weigh the same things.
Independent reviewers reverse plans when the record answers the criteria. Upload the denial letter; a senior reviewer reads it within 24 hours and tells you in writing whether it can be appealed and how. $0 upfront, 10% of what is recovered, nothing if we do not recover. Not a law firm.